GlaxoSmithKline: Asthma trials

The registry lists 261 Asthma studies with GlaxoSmithKline as lead sponsor. 7 are open to participants now and 132 have results posted.

Phase 1 63Phase 2 59Phase 3 61Phase 4 53No phase 26(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)RecruitingNCT07782996Phase 3
• A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)RecruitingNCT07780643Phase 3
• A Study of Depemokimab in Participants of 6 to 11 Years of AgeRecruitingNCT07671001Phase 3
• A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)RecruitingNCT07645248Phase 3
• A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 AsthmaRecruitingNCT07456033Phase 3
• Depemokimab Asthma Imaging and Bronchoscopy Sub-StudyRecruitingNCT06979323Phase 3
• A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 InclusiveRecruitingNCT06433921Phase 1
• A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild AsthmaCompletedNCT06702462Phase 1Results posted
• Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy ParticipantsCompletedNCT06506266Phase 1Results posted
• A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 InclusiveCompletedNCT06433908Phase 1Results posted
• Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled AsthmaActive, not recruitingNCT06372496Phase 4Results posted
• A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With AsthmaCompletedNCT06261957Phase 3Results posted
• Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy ParticipantsCompletedNCT05791565Phase 1Results posted
• A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult ParticipantsCompletedNCT05602025Phase 1Results posted
• An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)CompletedNCT05243680Phase 3Results posted
• Study of GSK3511294 in Healthy Chinese ParticipantsCompletedNCT05140200Phase 1Results posted
• Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled AsthmaCompletedNCT04937387Phase 3Results posted
• A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With AsthmaCompletedNCT04813354Phase 4Results posted
• Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic PhenotypeCompletedNCT04719832Phase 3Results posted
• A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypeCompletedNCT04718389Phase 3Results posted
• A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic PhenotypeCompletedNCT04718103Phase 3Results posted
• A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy ParticipantsCompletedNCT04366349Phase 1Results posted
• Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic AsthmaCompletedNCT04276233Phase 4Results posted
• A Safety and Efficacy Study of Mepolizumab in Subjects With Severe AsthmaCompletedNCT03562195Phase 3Results posted
• An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With AsthmaCompletedNCT03478657Phase 4Results posted
• Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)TerminatedNCT03393806Phase 2Results posted
• A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic SubjectsCompletedNCT03380429Phase 4Results posted
• Sensor and Electronic Health Records (EHR) Integration Pilot StudyCompletedNCT03357341Results posted
• Pediatric Ease of Use ELLIPTA ItemsCompletedNCT03315572Results posted
• First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate AsthmaCompletedNCT03287310Phase 1Results posted
• Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 YearsCompletedNCT03273946Results posted
• Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With AsthmaCompletedNCT03248128Phase 3Results posted
• Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe AsthmaCompletedNCT03207243Phase 2Results posted
• A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With AsthmaCompletedNCT03184987Phase 3Results posted
• Study of Mepolizumab Autoinjector in AsthmaticsCompletedNCT03099096Phase 3Results posted
• Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke CigarettesCompletedNCT03045887Phase 1Results posted
• Long Term Special Drug Use Investigation of MepolizumabCompletedNCT03028480Results posted
• Study of Mepolizumab Safety Syringe in AsthmaticsCompletedNCT03021304Phase 3Results posted
• A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised DrugCompletedNCT03014674Phase 3Results posted
• Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With AsthmaCompletedNCT03012061Phase 2Results posted
• Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic SubjectsCompletedNCT02991859Phase 2Results posted
• A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled AsthmaCompletedNCT02924688Phase 3Results posted
• Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a YearCompletedNCT02889809Phase 4Results posted
• Asthma Control Test Guided Treatment in Chinese SubjectsCompletedNCT02868281Phase 4Results posted
• Effect of the GSK2245035 on the Allergen-induced Asthmatic ResponseCompletedNCT02833974Phase 2Results posted
• Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct UseCompletedNCT02794480Phase 4Results posted
• Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)CompletedNCT02730351Phase 4Results posted
• A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.CompletedNCT02712047Phase 2Results posted
• Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma PatientsCompletedNCT02654145Phase 4Results posted
• Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With AsthmaCompletedNCT02586506Phase 4Results posted
• A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled AsthmaCompletedNCT02567708Phase 2Results posted
• Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma PatientsCompletedNCT02555371Phase 3Results posted
• Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With AsthmaCompletedNCT02502734Phase 3Results posted
• Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With AsthmaCompletedNCT02483975Phase 3Results posted
• Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Completing Treatment in Study TL7116958CompletedNCT02446613Phase 2Results posted
• A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent AsthmaCompletedNCT02446418Phase 3Results posted
• Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® InhalerCompletedNCT02416180Phase 4Results posted
• Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in ChildrenCompletedNCT02377427Phase 2Results posted
• An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent AsthmaCompletedNCT02301975Phase 3Results posted
• Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma ControlCompletedNCT02281318Phase 3Results posted
• A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With AsthmaCompletedNCT02233803Phase 4Results posted
• Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic ComponentCompletedNCT02164539Phase 2Results posted
• Indirect Cost of Illness Study of Moderate and Severe Asthma in QuebecCompletedNCT02153346Not applicableResults posted
• A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic SubjectsCompletedNCT02135692Phase 3Results posted
• Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial AsthmaCompletedNCT02113436Phase 4Results posted
• A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese SubjectsCompletedNCT02094937Phase 3Results posted
• A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of AgeCompletedNCT01995175Not applicableResults posted
• A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With AsthmaCompletedNCT01978119Phase 3Results posted
• A Study to Determine Long-term Safety of Mepolizumab in Asthmatic SubjectsCompletedNCT01842607Phase 3Results posted
• To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With AsthmaCompletedNCT01808339Phase 2Results posted
• An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in AsthmaCompletedNCT01706198Phase 3Results posted
• MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic SubjectsCompletedNCT01691859Phase 3Results posted
• Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory AsthmaCompletedNCT01691521Phase 3Results posted
• Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory AsthmaCompletedNCT01691508Phase 3Results posted
• Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of AsthmaCompletedNCT01687296Phase 3Results posted
• Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent AsthmaCompletedNCT01687283Phase 3Results posted
• An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.CompletedNCT01686633Phase 3Results posted
• A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With AsthmaCompletedNCT01641692Phase 2Results posted
• Dose-ranging Study of Vilanterol (VI) Inhalation Powder in ChildrenCompletedNCT01573767Phase 2Results posted
• Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With AsthmaCompletedNCT01573624Phase 2Results posted
• A Dose-ranging Study of Fluticasone Furoate (FF)CompletedNCT01563029Phase 2Results posted
• Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.CompletedNCT01498679Phase 3Results posted
• Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian AncestryCompletedNCT01498653Phase 3Results posted
• Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedNCT01494610Phase 1/2Results posted
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.CompletedNCT01475721Phase 4Results posted
• 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldCompletedNCT01462344Phase 4Results posted
• Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric SubjectsCompletedNCT01453296Phase 2Results posted
• Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD StudyCompletedNCT01453023Phase 2Results posted
• Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With AsthmaCompletedNCT01436110Phase 3Results posted
• Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With AsthmaCompletedNCT01436071Phase 3Results posted
• Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and AdolescentsCompletedNCT01431950Phase 3Results posted
• Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.CompletedNCT01400906Phase 2Results posted
• Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated EosinophilsCompletedNCT01366521Phase 2Results posted
• Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination TherapyCompletedNCT01347060Results posted
• Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma PatientsCompletedNCT01346852Results posted
• Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department VisitCompletedNCT01332357Results posted
• Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic PatientsCompletedNCT01332292Phase 2Results posted
• Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care PopulationCompletedNCT01328964Results posted
• A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung FunctionCompletedNCT01287065Phase 2Results posted
• A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With AsthmaCompletedNCT01244984Phase 3Results posted